TMCITreace Medical Concepts, Inc.
The Read
TMCI historically experiences large moves around 27% on average, with a 39.
The schedule
- Thu15Oct
Around October, investors are focused on the risk that a large orthopedic player steps up competitive intensity in bunion correction or that a patent challenge to Lapiplasty gains traction. From a $3.30 base price following a more volatile summer, a scenario where patents hold, competitive launches are slow, and Treace continues to differentiate could allow a rebound toward $3.90, while credible competitive encroachment or IP setbacks could pressure the stock toward $3.90.
- Tue12Jan
Management’s early 2027 strategic update is expected to outline Treace’s long-term plan for scaling its bunion and foot & ankle franchise, including potential partnerships or strategic alternatives. From a $1.20 base price reflecting prior stress, a credible multi-year growth and margin framework and renewed M&A interest could lift the stock toward $2.40, while a vague plan with no visible path to profitability or deal interest could see it drift down toward $2.40.
- Thu4Feb
Q3 2026 earnings will test whether Treace can convert product momentum into a credible path toward positive operating cash flow. From a $1.90 base price that assumes earlier headwinds, evidence of sustained double-digit procedure growth and improving gross margin could move the stock toward $2.60, while ongoing cash burn with little margin progress could pull it back toward $2.60.
- Sun14Feb
Q4 2026 earnings will provide a clean view of whether Treace’s 2026 initiatives are translating into sustainable growth and improving profitability. From a $2.40 base price, demonstrating accelerating revenue, improved gross margins, and contained opex could move the stock toward $1.40, while another year-end miss, continued cash burn, or lack of financing clarity could send it closer to $0.5.
- Sun16May
Q1 2027 earnings will show whether any momentum from the late-2026 strategic and financial updates is sustainable into the new year. From a $1.40 base price, continued execution on growth and cost controls could lift the stock toward $1.00, while renewed operational or funding setbacks could push it down toward $1.00.
Past
- Thu6Aug
Q2 2026 earnings will update investors on the revenue inflection after the recent downturn and on how Treace is managing margins and cash post-dilution. From a $5.40 base price assuming a modest pre-print drift, solid procedure growth, stable ASPs, and signs of operating leverage could support the stock around $4.8 after digestion, while another weak revenue print, widening losses, or renewed cash burn anxiety could drive it down toward $4.80.
- Thu16Jul
Update on Treace’s next-gen Lapiplasty and adjacent foot & ankle solutions, including early feedback on systems like SuperBite and broader bunion/TAM expansion. At a $4.66 base price, a constructive read-through on surgeon adoption and reimbursement could push the stock toward $5.40, while underwhelming adoption metrics or pricing pressure could see it retrace toward $5.40.
- Thu25Jun
Actual outcome: Bull · $4.21 at outcome
Although TMCI shares experienced a brief 5.4% pullback following the announcement of a dilutive equity offering to secure balance sheet runway, the stock successfully held above the $4.10 bull target, closing at $4.21 and continuing to climb to $4.66. The stock's resilience was driven by underlying operational momentum, highlighted by the first surgical case with the new HyperPlate XM Dynamic Compression Locking Implant System, which reinforced confidence in the company's expanding foot and ankle portfolio despite the dilution.
Management action to secure balance sheet runway after a rapid stock surge to $3.51.
- Fri8May
Actual outcome: Bull · $4.78 at outcome
Treace Medical Concepts reported its first-quarter 2026 financial results, beating quarterly revenue consensus estimates and posting a narrower loss per share than anticipated. Management reaffirmed its full-year 2026 revenue outlook, citing strong adoption of its new product portfolio and procedure volume momentum. The solid execution and reiterated guidance sparked a major rally in the stock following prior market weakness. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-08-05: +275.8% from 2026-03-20 (~5.8σ). Target date 2026-06-22 reached; move through 2026-08-05 observed.
Treace Medical Concepts reported its first-quarter 2026 financial results, beating quarterly revenue consensus estimates and posting a narrower loss per share than anticipated. Management reaffirmed its full-year 2026 revenue outlook, citing strong adoption of its new product portfolio and procedure volume momentum. The solid execution and reiterated guidance sparked a major rally in the stock following prior market weakness. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-08-05: +275.8% from 2026-03-20 (~5.8σ). Target date 2026-06-22 reached; move through 2026-08-05 observed.
- Tue31Mar
Actual outcome: Bull · $1.45 at outcome
The stock rallied well past the bull target, driven by positive product developments that overshadowed the anticipated dilution event. Specifically, Treace announced the first surgical cases with its new SuperBite Compression Screw System, expanding its portfolio to tap into incremental foot and ankle procedures. This operational momentum strengthened the company's commercial outlook and drove the upward price action.
Expected announcement of a necessary capital raise to address the liquidity crisis and provide cash runway through 2027.
- Fri27Feb
Actual outcome: Bear · $1.47 at outcome
While TMCI met EPS estimates, the stock plummeted 30% as the earnings report confirmed a critical liquidity crisis with only $7.68M in cash against a ~$16M quarterly burn rate. Despite management's attempt to pivot the narrative toward a 'transformational' expansion into broader bunion solutions, the immediate need for a highly dilutive capital raise drove the price well below the $1.70 bear floor.
Release of Q4 2025 results and full-year 2026 guidance. Given the $7.68M cash on hand and ~$16M quarterly burn, the market will panic over the immediate need for a highly dilutive capital raise.
